• Zura Bio completed enrollment in its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa, enrolling 247 participants.
• Topline TibuSHIELD results have not been presented; they are expected in Q4 2026, with the study assessing whether tibulizumab improves disease activity.
• Enrollment in the Phase 2 TibuSURE trial in early diffuse cutaneous systemic sclerosis is set to finish in early July, already exceeding its target of 80.
• TibuSURE topline results will be presented in the future, expected in H1 2027, with outcomes focused on whether tibulizumab improves skin-related disease.
• A third Phase 2 study is planned by year-end 2026 to expand tibulizumab into another immune-mediated disease; the indication will be disclosed later.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260629189605) on June 29, 2026, and is solely responsible for the information contained therein.